Skip to Content

'
Michael J. Keating, M.B., B.S.

Present Title & Affiliation

Primary Appointment

Professor of Medicine and Internist, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1966 St. Vincent's Hospital, Clinical School, Fitzroy, Victoria, Australia, MBBS, Medicine
1966 University of Melbourne, Melbourne, Australia, MBBS, Medicine

Postgraduate Training

1974-1975 Fellow, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, TX
1971-1973 Third Assistant, St. Vincent's Hospital, University of Melbourne, Melbourne, Australia
1970-1971 Senior Registrar, St. Vincent's Hospital, University of Melbourne, Melbourne, Australia
1970 Fellow, Royal Australasian College of Physicians, Sydney, Australia
1969-1970 Medical Registrar, St. Vincent's Hospital, Melbourne, Australia
1967-1968 Residency in Medicine Surgery, St. Vincent's Hospital, Fitzroy, Victoria, Australia

Selected Publications

Peer-Reviewed Original Research Articles

1. Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 115(13):2824-2836, 7/2009. PMID: 19402170.
2. Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ, Thomas DA, Pierce S, Kantarjian H, Verstovsek S. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: Applicability at the time of diagnosis and later during disease course. Blood 113(18):4171-4178, 4/2009. e-Pub 1/2009. PMID: 19131547.
3. Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ, Kantarjian HM, Keating MJ. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 27(6):904-910, 2/2009. e-Pub 12/2008. PMID: 19114699.
4. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. Relative value Of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112(5):1923-1930, 9/2008. e-Pub 6/2008. PMCID: PMC2518894.
5. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112(4):975-980, 8/2008. e-Pub 4/2008. PMID: 18411418.
6. Keating MJ, Bach C, Yasothan U, Kirkpatrick P. Bendamustine. Nat Rev Drug Discov 7(6):473-474, 6/2008. PMID: 18511926.
7. Borthakur G, O'Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S, Keating MJ. Immune anaemias in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide and rituximab - incidence and predictors. Br J Haematol 136(6):800-805, 2007.
8. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109(11):4679-4685, 2007. PMID: 17299097.
9. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ. Hodgkin's transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 107(6):1294-1302, 9/2006. PMID: 16902984.
10. Ferrajoli A, Faderl S, Keating MJ. Monoclonal antibodies in chronic lymphocytic leukemia. Expert Rev Anticancer Ther 6(9):1231-1238, 9/2006. PMID: 17020457.
11. O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 7(2):125-130, 9/2006. PMID: 17026823.
12. Tsimberidou AM, Keating MJ, Bueso-Ramos CE, Kurzrock R. Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma 47(5):827-836, 5/2006. PMID: 16753866.
13. Wierda WG, Kipps TJ, Keating MJ. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol 23(26):6325-6332, 9/2005. PMID: 16155015.
14. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23(18):4079-4088, 6/2005. e-Pub 3/2005. PMID: 15767648.
15. Faderl SJ, Keating MJ. Treatment of chronic lymphocytic leukemia. Curr Hematol Rep 4(1):31-38, 1/2005. PMID: 15610657.
16. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology 23(18):4070-4078, 2005. PMID: 15767647.

Last updated: 8/20/2013